Announcement • Jul 02
Artelo Biosciences Announces New Data Supporting ART26.12 As A Potential First-In-Class Therapy For Chronic Pain Associated With Spinal Cord Injury Artelo Biosciences, Inc. announced positive new data from a preclinical study in neuropathic pain from spinal cord injury. The findings are being presented at the International Cannabinoid Research Society 2026 Annual Symposium in Dijon, France and the Company believes the results support the broad therapeutic potential of ART26.12, Artelo’s proprietary clinical stage selective fatty acid binding protein 5 (FABP5) inhibitor, currently progressing in Phase 1 development. The presentation titled Inhibition of Fatty Acid Binding Protein 5 Alleviates Neuropathic Pain Following Spinal Cord Injury in Mice is being delivered by Martin Kaczocha, Ph.D., Professor of Anesthesiology at Stony Brook University, New York. The new evidence demonstrated that FABP5 inhibition alleviated neuropathic pain associated with spinal cord injury in an animal model. These data expand the evidence regarding the potential clinical utility of ART26.12 beyond previously reported target indications in painful neuropathies. Nearly 90% of people with a spinal cord injury suffer with some form of chronic pain, up to 60% of individuals living with spinal cord injuries experience neuropathic pain, a chronic type of nerve pain which is frequently resistant to currently available therapies. In the study conducted at Stony Brook University, investigators evaluated the effects of ART26.12 in a validated mouse model of spinal cord injury-induced neuropathic pain. Results demonstrated that selective FABP5 inhibition: Reduced mechanical hypersensitivity associated with nerve injury; Decreased spontaneous pain-related behaviors; Suppressed nociceptor hyperexcitability; Improved pain outcomes following oral administration. FABP5 inhibition suppresses nociceptor hypersensitivity and spontaneous pain behaviors following spinal cord injury. These data support continued exploration of FABP5 inhibition as a novel analgesic strategy. These findings suggest that modulation of lipid-signaling pathways and, in particular, FABP5 inhibition, may address key biological mechanisms underlying neuropathic pain and support further investigation of ART26.12 in multiple chronic pain conditions. ART26.12, Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, is under development as a novel, peripherally acting, non-opioid, non-steroidal analgesic, initially for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). Human studies with ART26.12 have demonstrated a favorable safety profile with no serious adverse events, as well as predictable, linear pharmacokinetics and dosing flexibility in both fed and fasted states. Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids important to normal cellular function. In addition to ART26.12, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders. Announcement • Jul 01
Artelo Biosciences Presents Evidence for A Common Lipid-Signaling Link Across Multiple Potential Indications for Its Fabp5 Inhibitor Platform At Icrs 2026 Artelo Biosciences announced results utilizing multi-omics analyses that identified a potential mechanistic links across disease models with ART26.12, the Company’s lead selective Fatty Acid Binding Protein 5 (FABP5) inhibitor that was presented at the International Cannabinoid Research Society (ICRS) 2026 Annual Symposium being held in Dijon, France. Artelo researchers evaluated datasets generated across multiple disease models, tissues, and experimental systems to identify common biological pathways associated with treatment with ART26.12, Artelo's FABP5 inhibitor currently in Phase 1 testing. The analyses revealed consistent modulation of the pro-inflammatory lipid linoleic acid and related lipid-signaling pathways across indications, suggesting a potential mechanistic link underlying the broad therapeutic activity observed with FABP5 inhibition. This finding is consistent with a recent high-impact research paper published in Science by an independent group from Cornell University which demonstrated the linoleic acid-FABP5 axis was a key driver of cancer growth activity in a model of triple negative breast cancer. ART26.12, Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, is under development as a novel, peripherally acting, non-opioid, non-steroidal analgesic, initially for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). Human studies with ART26.12 have demonstrated a favorable safety profile with no serious adverse events, as well as predictable, linear pharmacokinetics and dosing flexibility in both fed and fasted states. Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids important to normal cellular function. In addition to ART26.12, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders. ARTL
Live News • Jun 30
Artelo Biosciences Unveils Positive Phase 1 Data for FABP5 Inhibitor ART26.12 at ICRS 2026 Artelo Biosciences reported positive Phase 1 data for its FABP5 inhibitor ART26.12 at the ICRS 2026 symposium, showing the drug was generally well-tolerated with dose-proportional exposure and plasma levels above projected therapeutic thresholds.
Multi-omics work, including proteomic and lipidomic analyses, found consistent modulation of the pro-inflammatory lipid linoleic acid and linked pathways, suggesting ART26.12 could have relevance across several inflammation-related indications and support broader use of Artelo’s FABP5 inhibitor platform.
Artelo Biosciences shares trade at about $1.10, with the stock down 85.5% over the past 90 days, so any future development decisions around ART26.12 may be closely watched relative to the company’s clinical focus and funding priorities.
The read-through is that pipeline progress is becoming central to how you might assess Artelo’s risk profile, since future value depends heavily on the clinical and regulatory path for ART26.12 and related programs. 
